Gordon Konstantin, Gulidov Igor, Gogolin Danil, Lepilina Olga, Golovanova Olga, Semenov Alexey, Dujenko Sergey, Medvedeva Kira, Koryakin Sergey, Ivanov Sergey, Kaprin Andrey
Department of Proton Therapy, A. Tsyb Medical Radiological Research Center, Obninsk, Russian Federation.
Department of Dosimetry, A. Tsyb Medical Radiological Research Center, Obninsk, Russian Federation.
Case Rep Oncol. 2021 Feb 25;14(1):78-84. doi: 10.1159/000513030. eCollection 2021 Jan-Apr.
Orbital hemangiopericytomas (HPCs) are rare mesenchymal tumors with a high tendency to recur. Treatment options are quite limited in case of a relapse, but re-irradiation can be useful. Most of the available data limit the possibility of re-irradiation, while novel techniques (e.g., pencil beam proton therapy [PT]) open new approaches for the safe repeating of treatment. To the best of our knowledge, this is the first well-documented case of multi-times (>3) irradiation of tumors located intracranially. The case reported here describes orbital HPCs with proton irradiation performed two times since 1999 in a 30-year-old woman with a medical history as well as surgery followed by conventional radiotherapy (RT) and chemotherapy, and two times stereotactic RT (in 2009 and 2013). In 2016 the patient came to our hospital with the 3rd relapse of the tumor, located in the left orbit, with an intracranial part, involving cavernous sinus, which was close to the temporal lobe. The 4th course of irradiation was done in May to June 2016 by pencil beam PT. Radiation necrosis occurred after 2 years and was treated with bevacizumab (BVZ). Three years later, another relapse was treated with PT and BVZ. The 9-month follow-up showed complete tumor response without signs of brain toxicity. The patient died due to a brain abscess 1 year after the 5th irradiation. This case shows a possibility of irradiation, applied 5 times to the same location, with promising results and manageable toxicity.
眼眶血管外皮细胞瘤(HPCs)是一种罕见的间叶组织肿瘤,具有很高的复发倾向。复发时的治疗选择非常有限,但再次放疗可能会有帮助。现有的大多数数据限制了再次放疗的可能性,而新技术(如笔形束质子治疗[PT])为安全重复治疗开辟了新途径。据我们所知,这是首例有充分记录的对颅内肿瘤进行多次(>3次)放疗的病例。本文报道的病例描述了一名30岁女性眼眶HPCs的情况,自1999年以来该患者接受了两次质子放疗,此前还接受了手术、传统放疗(RT)和化疗,以及两次立体定向放疗(分别在2009年和2013年)。2016年,患者因肿瘤第三次复发前来我院,肿瘤位于左侧眼眶,有颅内部分,累及海绵窦,靠近颞叶。2016年5月至6月通过笔形束PT进行了第四次放疗。2年后发生放射性坏死,采用贝伐单抗(BVZ)治疗。3年后,另一次复发采用PT和BVZ治疗。9个月的随访显示肿瘤完全缓解,无脑毒性迹象。患者在第五次放疗后1年因脑脓肿死亡。该病例显示了对同一部位进行5次放疗的可能性,结果良好且毒性可控。